Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

246 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Cochrane review on brain [¹⁸F]FDG PET in dementia: limitations and future perspectives.
Morbelli S, Garibotto V, Van De Giessen E, Arbizu J, Chételat G, Drezgza A, Hesse S, Lammertsma AA, Law I, Pappata' S, Payoux P, Pagani M; European Association of Nuclear Medicine. Morbelli S, et al. Among authors: chetelat g. Eur J Nucl Med Mol Imaging. 2015 Sep;42(10):1487-91. doi: 10.1007/s00259-015-3098-2. Eur J Nucl Med Mol Imaging. 2015. PMID: 26067090 Review. No abstract available.
Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment.
Camus V, Payoux P, Barré L, Desgranges B, Voisin T, Tauber C, La Joie R, Tafani M, Hommet C, Chételat G, Mondon K, de La Sayette V, Cottier JP, Beaufils E, Ribeiro MJ, Gissot V, Vierron E, Vercouillie J, Vellas B, Eustache F, Guilloteau D. Camus V, et al. Among authors: chetelat g. Eur J Nucl Med Mol Imaging. 2012 Apr;39(4):621-31. doi: 10.1007/s00259-011-2021-8. Epub 2012 Jan 18. Eur J Nucl Med Mol Imaging. 2012. PMID: 22252372 Free PMC article. Clinical Trial.
Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.
Ossenkoppele R, Jansen WJ, Rabinovici GD, Knol DL, van der Flier WM, van Berckel BN, Scheltens P, Visser PJ; Amyloid PET Study Group; Verfaillie SC, Zwan MD, Adriaanse SM, Lammertsma AA, Barkhof F, Jagust WJ, Miller BL, Rosen HJ, Landau SM, Villemagne VL, Rowe CC, Lee DY, Na DL, Seo SW, Sarazin M, Roe CM, Sabri O, Barthel H, Koglin N, Hodges J, Leyton CE, Vandenberghe R, van Laere K, Drzezga A, Forster S, Grimmer T, Sánchez-Juan P, Carril JM, Mok V, Camus V, Klunk WE, Cohen AD, Meyer PT, Hellwig S, Newberg A, Frederiksen KS, Fleisher AS, Mintun MA, Wolk DA, Nordberg A, Rinne JO, Chételat G, Lleo A, Blesa R, Fortea J, Madsen K, Rodrigue KM, Brooks DJ. Ossenkoppele R, et al. Among authors: chetelat g. JAMA. 2015 May 19;313(19):1939-49. doi: 10.1001/jama.2015.4669. JAMA. 2015. PMID: 25988463 Free PMC article.
The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis.
Morbelli S, Arbizu J, Booij J, Chen MK, Chetelat G, Cross DJ, Djekidel M, Drzezga A, Ekmekcioglu O, Garibotto V, Hesse S, Ishii K, Jafari L, Lammertsma AA, Law I, Mathews D, Minoshima S, Mosci K, Pagani M, Pappata S, Silverman DH, Signore A, Van De Giessen E, Villemagne V, Barthel H; European Association of Nuclear Medicine (EANM) and of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Morbelli S, et al. Among authors: chetelat g. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):353-357. doi: 10.1007/s00259-016-3589-9. Epub 2016 Dec 6. Eur J Nucl Med Mol Imaging. 2017. PMID: 27924371 No abstract available.
Erratum to: The need of standardization and of large clinical studies in an emerging indication of [18 F]FDG PET: the autoimmune encephalitis.
Morbelli S, Arbizu J, Booij J, Chen MK, Chetelat G, Cross DJ, Djekidel M, Drzezga A, Ekmekcioglu O, Garibotto V, Hesse S, Ishii K, Jafari L, Lammertsma AA, Law I, Mathews D, Minoshima S, Mosci K, Pagani M, Pappata S, Silverman DH, Signore A, Van De Giessen E, Villemagne V, Barthel H; European Association of Nuclear Medicine (EANM) and of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Morbelli S, et al. Among authors: chetelat g. Eur J Nucl Med Mol Imaging. 2017 Mar;44(3):559-560. doi: 10.1007/s00259-016-3598-8. Eur J Nucl Med Mol Imaging. 2017. PMID: 27987029 No abstract available.
Secondary prevention of Alzheimer's dementia: neuroimaging contributions.
Ten Kate M, Ingala S, Schwarz AJ, Fox NC, Chételat G, van Berckel BNM, Ewers M, Foley C, Gispert JD, Hill D, Irizarry MC, Lammertsma AA, Molinuevo JL, Ritchie C, Scheltens P, Schmidt ME, Visser PJ, Waldman A, Wardlaw J, Haller S, Barkhof F. Ten Kate M, et al. Among authors: chetelat g. Alzheimers Res Ther. 2018 Oct 30;10(1):112. doi: 10.1186/s13195-018-0438-z. Alzheimers Res Ther. 2018. PMID: 30376881 Free PMC article. Review.
Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias.
Chételat G, Arbizu J, Barthel H, Garibotto V, Law I, Morbelli S, van de Giessen E, Agosta F, Barkhof F, Brooks DJ, Carrillo MC, Dubois B, Fjell AM, Frisoni GB, Hansson O, Herholz K, Hutton BF, Jack CR Jr, Lammertsma AA, Landau SM, Minoshima S, Nobili F, Nordberg A, Ossenkoppele R, Oyen WJG, Perani D, Rabinovici GD, Scheltens P, Villemagne VL, Zetterberg H, Drzezga A. Chételat G, et al. Lancet Neurol. 2020 Nov;19(11):951-962. doi: 10.1016/S1474-4422(20)30314-8. Lancet Neurol. 2020. PMID: 33098804 Review.
Finding our way through the labyrinth of dementia biomarkers.
Chételat G, Arbizu J, Barthel H, Garibotto V, Lammertsma AA, Law I, Morbelli S, van de Giessen E, Drzezga A. Chételat G, et al. Eur J Nucl Med Mol Imaging. 2021 Jul;48(8):2320-2324. doi: 10.1007/s00259-021-05301-7. Eur J Nucl Med Mol Imaging. 2021. PMID: 33876260 No abstract available.
Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services-part 2 of 6.
Ranson JM, Rittman T, Hayat S, Brayne C, Jessen F, Blennow K, van Duijn C, Barkhof F, Tang E, Mummery CJ, Stephan BCM, Altomare D, Frisoni GB, Ribaldi F, Molinuevo JL, Scheltens P, Llewellyn DJ; European Task Force for Brain Health Services. Ranson JM, et al. Alzheimers Res Ther. 2021 Oct 11;13(1):169. doi: 10.1186/s13195-021-00895-4. Alzheimers Res Ther. 2021. PMID: 34635138 Free PMC article. Review.
Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services-part 4 of 6.
Solomon A, Stephen R, Altomare D, Carrera E, Frisoni GB, Kulmala J, Molinuevo JL, Nilsson P, Ngandu T, Ribaldi F, Vellas B, Scheltens P, Kivipelto M; European Task Force for Brain Health Services. Solomon A, et al. Alzheimers Res Ther. 2021 Oct 11;13(1):171. doi: 10.1186/s13195-021-00875-8. Alzheimers Res Ther. 2021. PMID: 34635167 Free PMC article. Review.
246 results